Integrated BioPharma, Inc.

Total Valuation

Integrated BioPharma, Inc. carries a market capitalization of 4.66M, placing it among publicly traded companies globally. Its enterprise value stands at 5.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Integrated BioPharma, Inc. currently has 31.06M shares outstanding.

Valuation Ratios

Integrated BioPharma, Inc. trades at a trailing price-to-earnings ratio of 26.57. The price-to-sales ratio is 0.17, and the price-to-book ratio stands at -0.26.

Enterprise Valuation

On an enterprise value basis, Integrated BioPharma, Inc. trades at an EV/EBITDA multiple of 62.75 and an EV/FCF ratio of 1.83. The EV/Sales ratio of 0.12 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.87 provides insight into valuation relative to core operating earnings.

Financial Position

Integrated BioPharma, Inc. maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Integrated BioPharma, Inc. has paid 536,000.00 in income taxes, reflecting an effective tax rate of 167.16.

Stock Price Statistics

Integrated BioPharma, Inc.'s stock has declined approximately -58.33333% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.28.

Income Statement

Over the trailing twelve months, Integrated BioPharma, Inc. generated 48.25M in revenue and converted that into -1.65M in net income, yielding earnings per share of -0.05. EBITDA reached 94,000.00, while operating income came in at -1.25M.

Balance Sheet

Integrated BioPharma, Inc. holds 5.83M in cash and equivalents against 3.35M in total debt, resulting in a net debt position of -5.83M. Total book value stands at -32.83M, with working capital of 12.45M providing operational flexibility.

Cash Flow

Integrated BioPharma, Inc. produced 3.03M in operating cash flow over the past twelve months. After subtracting -201,000.00 in capital expenditures, free cash flow totaled 2.83M - equivalent to 0.09 per share.

Margins

Integrated BioPharma, Inc. operates with a gross margin of 4.64, reflecting its pricing power and cost economics. The operating margin of -2.58 and net profit margin of -3.43 provide insight into operational efficiency.

Dividends & Yields

Scores

Integrated BioPharma, Inc. posts an Altman Z-Score of 1.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.